**Supplementary File 3: List of Excluded Articles**

Reason: Newer guideline available

1. Cibulka MT, White DM, Woehrle J, et al (2009) Hip pain and mobility deficits--hip osteoarthritis: clinical practice guidelines linked to the international classification of functioning, disability, and health from the orthopaedic section of the American Physical Therapy Association. J Orthop Sports Phys Ther 39:A1-25. https://doi.org/[10.2519/jospt.2009.0301](https://doi.org/10.2519/jospt.2009.0301)
2. Croke LM (2014) Treatment of Knee Osteoarthritis: A Clinical Practice Guideline from the AAOS. AFP 89:918–920
3. National Collaborating Centre for Chronic Conditions (UK) (2009) Rheumatoid Arthritis: National Clinical Guideline for Management and Treatment in Adults. Royal College of Physicians (UK), London
4. Fonseca JE, Canhão H, Reis P, et al (2010) Portuguese guidelines for the use of biological agents in rheumatoid arthritis - March 2010 update. Acta Reumatol Port 35:95–98
5. Saag KG, Gim GT, Patkar NM, et al (2008) American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis. Arthritis Rheum 59:762–784. <https://doi.org/10.1002/art.23721>
6. Richmond J, Hunter D, Irrgang J, et al (2010) American Academy of Orthopaedic Surgeons clinical practice guideline on the treatment of osteoarthritis (OA) of the knee. J Bone Joint Surg Am 92:990–993. <https://doi.org/10.2106/JBJS.I.00982>

Reason: Guideline summary

1. Bukhari M, Abernethy R, Deighton C, et al (2011) BSR and BHPR guidelines on the use of rituximab in rheumatoid arthritis. Rheumatology (Oxford) 50:2311–2313. <https://doi.org/10.1093/rheumatology/ker106a>

Reason: Irretrievable

1. Albrecht K, Krüger K, Wollenhaupt J, et al (2014) German guidelines for the sequential medical treatment of rheumatoid arthritis with traditional and biologic disease-modifying antirheumatic drugs. Rheumatol Int 34:1–9. <https://doi.org/10.1007/s00296-013-2848-3>
2. Bykerk VP, Akhavan P, Hazlewood GS, et al (2012) Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs. J Rheumatol 39:1559–1582. <https://doi.org/10.3899/jrheum.110207>
3. Cardiel MH, Díaz-Borjón A, Vázquez del Mercado Espinosa M, et al (2014) Actualización de la Guía Mexicana para el Tratamiento Farmacológico de la Artritis Reumatoide del Colegio Mexicano de Reumatología. Reumatol Clin 10:227–240. <https://doi.org/10.1016/j.reuma.2013.10.006>
4. Forestier R, André-Vert J, Guillez P, et al (2009) Non-drug treatment (excluding surgery) in rheumatoid arthritis: Clinical practice guidelines. Joint Bone Spine 76:691–698. <https://doi.org/10.1016/j.jbspin.2009.01.017>
5. Gaujoux-Viala C, Gossec L, Cantagrel A, et al (2014) Recommendations of the French Society for Rheumatology for managing rheumatoid arthritis. Joint Bone Spine 81:287–297. <https://doi.org/10.1016/j.jbspin.2014.05.002>
6. Hochberg MC, Altman RD, April KT, et al (2012) American College of Rheumatology 2012 recommendations for the use of nonpharmacologic and pharmacologic therapies in osteoarthritis of the hand, hip, and knee. Arthritis Care Res (Hoboken) 64:465–474. <https://doi.org/10.1002/acr.21596>
7. Izquierdo R, Voloshin I, Edwards S, et al (2010) Treatment of Glenohumeral Osteoarthritis. JAAOS - Journal of the American Academy of Orthopaedic Surgeons 18:375–382. https://doi.org/[10.5435/00124635-201006000-00010](https://doi.org/10.5435/00124635-201006000-00010)
8. Kamaruzaman H (2013) CPG Management of Osteoarthritis (2nd Edition). Ministry of Health, Malaysia
9. Kameda H, Fujii T, Nakajima A, et al (2019) Japan College of Rheumatology guideline for the use of methotrexate in patients with rheumatoid arthritis. Mod Rheumatol 29:31–40. <https://doi.org/10.1080/14397595.2018.1472358>
10. Malaviya AP, Ledingham J, Bloxham J, et al (2014) The 2013 BSR and BHPR guideline for the use of intravenous tocilizumab in the treatment of adult patients with rheumatoid arthritis. Rheumatology (Oxford) 53:1344–1346. <https://doi.org/10.1093/rheumatology/keu168>
11. McGrory B, Weber K, Lynott J, et al (2016) The American Academy of Orthopaedic Surgeons Evidence-Based Clinical Practice Guideline on Surgical Management of Osteoarthritis of the Knee. J Bone Joint Surg 98:688–692. <https://doi.org/10.2106/JBJS.15.01311>
12. Singh JA, Saag KG, Bridges SL, et al (2016) 2015 American College of Rheumatology Guideline for the Treatment of Rheumatoid Arthritis. Arthritis Rheumatol 68:1–26. <https://doi.org/10.1002/art.39480>
13. Smolen JS, Landewé R, Bijlsma J, et al (2017) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update. Ann Rheum Dis 76:960–977. <https://doi.org/10.1136/annrheumdis-2016-210715>
14. Smolen JS, Landewé R, Breedveld FC, et al (2014) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 73:492–509. <https://doi.org/10.1136/annrheumdis-2013-204573>
15. Spanish Society of Rheumatology Update of the clinical practice guideline for the management of rheumatoid arthritis in Spain Clinical Practice Guidelines. Guideline Central. <https://www.guidelinecentral.com/summaries/update-of-the-clinical-practice-guideline-for-the-management-of-rheumatoid-arthritis-in-spain/#section-date>.